Equity Residential (NYSE:EQR) Q4 2025 Earnings call February 06, 2026 10:00 AM ET Company ParticipantsAlexander Goldfarb - Managing DirectorBob Garechana - Chief Investment OfficerBrad Heffern - DirectorBret McLeod - CFOHaendel St. Juste - Managing DirectorJamie Feldman - Managing DirectorJohn Pawlowski - Managing DirectorLinda Tsai - Senior Vice PresidentMark Parrell - President and CEOMartin McKenna - Head of Investor RelationsMichael Manelis - Chief Operating OfficerRich Hightower - Managing DirectorConf ...

MarketAxess (NasdaqGS:MKTX) Q4 2025 Earnings call February 06, 2026 10:00 AM ET Company ParticipantsChris Concannon - CEOIlene Fiszel Bieler - CFOStephen Davidson - Head of Investor RelationsConference Call ParticipantsAlex Blostein - Managing Director & Senior Equity Research Analyst, Financial ServicesChris O’Brien - for Ben Budish, Director & Senior Equity Research AnalystDan Fannon - Managing Director & Senior Research AnalystEli Abboud - Equity Research AnalystJeff Schmitt - Senior Equity Research Anal ...

Flowserve (NYSE:FLS) Q4 2025 Earnings call February 06, 2026 10:00 AM ET Company ParticipantsAmit Mehrotra - Managing Director and Industrial Sector HeadAmy Schwetz - CFOBrian Ezzell - VP of Investor RelationsDeane Dray - Managing DirectorJoe Giordano - Managing DirectorScott Rowe - President and CEOConference Call ParticipantsBrett Linzey - Managing Director & Senior Equity Research AnalystMike Halloran - Associate Director of Research and Senior Research AnalystNone - AnalystNone - AnalystOperatorGood day ...

MarketAxess (NasdaqGS:MKTX) Q4 2025 Earnings call February 06, 2026 10:00 AM ET Company ParticipantsChris Concannon - CEOIlene Fiszel Bieler - CFOStephen Davidson - Head of Investor RelationsConference Call ParticipantsAlex Blostein - Managing Director & Senior Equity Research Analyst, Financial ServicesChris O’Brien - for Ben Budish, Director & Senior Equity Research AnalystDan Fannon - Managing Director & Senior Research AnalystEli Abboud - Equity Research AnalystJeff Schmitt - Senior Equity Research Anal ...

Encompass Health (NYSE:EHC) Q4 2025 Earnings call February 06, 2026 10:00 AM ET Company ParticipantsAndrew Mok - DirectorDoug Coltharp - EVP and CFOJared Haase - Equity Research AssociateMark Miller - Chief Investor Relations OfficerMark Tarr - President and CEOPatrick Tuer - EVP and COOWhit Mayo - Senior Managing DirectorConference Call ParticipantsAnn Hynes - Senior Healthcare Services Equity Analyst and Managing DirectorBrian Tanquilut - Senior Analyst in Healthcare Services, and HCIT/Digital Health Equi ...

Reinsurance Group of America (NYSE:RGA) Q4 2025 Earnings call February 06, 2026 10:00 AM ET Company ParticipantsAxel André - EVP and CFOJeff Hopson - SVP of Investor RelationsJonathan Porter - EVP and Global Chief Risk OfficerLeslie Barbi - EVP and Chief Investment OfficerThomas Gallagher - Senior Managing DirectorTony Cheng - President and CEOWes Carmichael - Executive DirectorConference Call ParticipantsAlex Scott - Insurance Research AnalystJimmy Bhullar - Equity Research AnalystJoel Hurwitz - AnalystJoh ...

Financial Data and Key Metrics Changes - The company reported Q4 operating EPS of $7.75 per share, marking the second consecutive record quarter in earnings [6] - Adjusted operating return on equity (ROE) for the trailing 12 months was 15.7%, exceeding the intermediate-term target range of 13%-15% [6][17] - For the full year 2025, the company achieved record operating EPS and increased the value of Inforce business margins by 18% [6][10] Business Line Data and Key Metrics Changes - The U.S. market showed favorable results driven by management actions and variable investment income, with individual life mortality in line with expectations [8] - EMEA results reflected strong volume growth and favorable experience, with full-year pre-tax earnings up 35% [11] - APAC continued to see growth momentum, with pre-tax operating income up 18% for the year [10][11] Market Data and Key Metrics Changes - Premium growth was 7.4% year-to-date on a constant currency basis, benefiting from strong growth across North America, EMEA, and APAC [18] - The U.S. healthcare business has approximately $400 million of annual premium, generating about $25 million of pre-tax run rate earnings [39] Company Strategy and Development Direction - The company is focused on a proactive business approach, optimizing its balance sheet, operational scaling, and capital stewardship to generate long-term shareholder value [14][15] - A strategic review led to the decision to exit the group healthcare lines of business, with a focus on deploying capital in strategically aligned businesses [12][39] - The company aims to maintain a balanced approach to capital deployment, targeting a total payout ratio of 20%-30% for buybacks and dividends [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to generate attractive shareholder value going forward, supported by a strong pipeline of opportunities across various regions [16][77] - The company anticipates a more limited financial impact from Inforce management actions in 2026 compared to recent years [22][83] - Higher interest rates are viewed positively for overall earnings, with modest exposure to disintermediation risk from higher rates [89] Other Important Information - The company successfully repurchased $50 million of shares in Q4, totaling $125 million since reinstating buybacks [10][18] - The effective tax rate for Q4 was 23.8%, with expectations for 2026 in the range of 22%-23% [18] Q&A Session Summary Question: Capital allocation and payout ratio - Management confirmed the target of a 20%-30% total payout ratio while maintaining flexibility for capital deployment [32] Question: Group health rate actions and exit strategy - Significant rate actions were taken, including a 40% average increase, and the decision to exit the group healthcare business was driven by strategic alignment [38][39] Question: Performance of the Equitable block - The Equitable transaction is expected to generate earnings of $160-$170 million in 2026, with various drivers of economic upside identified [45][46] Question: Long-term care risk transfer deal performance - Management expressed satisfaction with the long-term care business performance, aligning with risk appetite and return expectations [57] Question: Exposure to software-related companies and AI disruption - The company has modest exposure to software lending and actively assesses the impact of AI on the investment portfolio [62] Question: Regulatory changes in Europe and competition - Management noted no significant competitive threats arising from regulatory changes in Europe, focusing on opportunities with both asset and biometric risks [72][73]

Financial Data and Key Metrics Changes - In 2025, the company achieved a 6% increase in sales volume year-over-year, despite a challenging market environment marked by global overcapacity and subdued steel production trends [4][5] - The average selling price for the fourth quarter was approximately $4,000 per metric ton, reflecting a 9% decline year-over-year and a 5% sequential decline from the third quarter [17] - The company reported a net loss of $65 million or $2.50 per share for the fourth quarter, compared to a net loss of $49 million or $1.92 per share in the prior year [21] Business Line Data and Key Metrics Changes - The U.S. sales volume grew by 48% for the full year and by 83% in the fourth quarter, indicating a successful shift towards regions with stronger pricing fundamentals [5][17] - The company's production volume for the fourth quarter was approximately 28,000 metric tons, resulting in a capacity utilization rate of 60% [16] Market Data and Key Metrics Changes - Global steel production outside of China was 843 million tons in 2025, up less than 1% compared to the prior year, with a global utilization rate of approximately 67% [8][9] - In North America, steel production increased by 1% in 2025, driven by a 3% year-over-year growth in the United States [9] Company Strategy and Development Direction - The company aims to grow sales volume by 5%-10% year-over-year in 2026, with a continued focus on shifting geographic mix towards the U.S. [26][27] - Management is evaluating opportunities for trade or policymaking support and potential strategic partnerships to enhance efficiency and long-term value creation [15] Management Comments on Operating Environment and Future Outlook - The management highlighted the need for structural changes in the supply chain to address the overcapacity issue in the graphite electrode industry, which threatens long-term viability [14][36] - There are indicators of a rebound in the steel market, with projected global steel demand growth of 3.5% year-over-year for 2026 [10][11] Other Important Information - The company ended 2025 with a liquidity position of $340 million, which includes $138 million in cash, enabling it to maintain stability amid industry challenges [7][24] - The total recordable incident rate improved to 0.41 in 2025, representing the best safety performance on record for the company [7] Q&A Session Summary Question: Has aggressive competitor pricing worsened, particularly in the U.S.? - Management noted that pricing pressure is observed globally, driven by imports and aggressive pricing behaviors from competitors, particularly from China and India [42][45] Question: Is it reasonable to assume that realized pricing will be lower in 2026? - Management refrained from providing specific price guidance but indicated that pricing levels heading into 2026 are not better than those observed in 2025 [46] Question: How does the company plan to win back market share amid aggressive pricing? - The company will focus on enhancing its value proposition through R&D and customer partnerships, while being selective in regions where price competition is fierce [56] Question: What is the company's liquidity position to navigate the downturn? - The company has $340 million in liquidity and has taken decisive actions to preserve and enhance this liquidity amid ongoing market challenges [65] Question: What is the impact of Indian tariffs on the U.S. market? - Management expressed confidence in their position heading into 2026, despite the reduction of tariffs on Indian imports, anticipating overall volume growth [71] Question: What is the current supply picture of graphite electrodes coming out of China? - Management indicated that Chinese exports continue to pressure the global market, with significant overcapacity affecting pricing dynamics [78]

Financial Data and Key Metrics Changes - Canopy Growth ended Q3 with CAD 371 million in cash and cash equivalents, and a net cash position of CAD 146 million, marking a strong financial foundation [4][10] - The company achieved its slimmest Adjusted EBITDA loss to date of CAD 3 million, reflecting improved cost discipline and execution [14] - Free Cash Flow was an outflow of CAD 19 million in Q3, down from CAD 28 million in the same period last year, primarily due to reduced cash interest payments and working capital movements [14] Business Line Data and Key Metrics Changes - Canadian Medical cannabis net revenue grew 15% year-over-year to CAD 23 million, marking the sixth consecutive quarter of growth [6][11] - Canadian Adult Use cannabis revenue increased 8% year-over-year to CAD 23 million, driven by growth in pre-rolls and vapes [7][12] - International cannabis sales increased 22% quarter-over-quarter, indicating stabilization and return to growth [8][12] - Storz & Bickel net revenue grew 45% sequentially to CAD 23 million, driven by strong seasonal sales and the introduction of the new VEAZY vaporizer [8][12] Market Data and Key Metrics Changes - The Canadian adult use market is projected to grow at 4%-6% annually, with the total market size around CAD 5 billion [36] - The Canadian medical market is estimated to be between CAD 300 million and CAD 400 million, with veterans representing a significant portion of this market [36] Company Strategy and Development Direction - The company is focused on elevating the quality of its brands, strengthening product innovation, and improving the quality and cost of its flower [7][19] - Canopy Growth aims to unlock growth in Europe, enhance its presence in the Canadian medical cannabis market, and leverage MTL Cannabis's capabilities for operational improvements [5][19] - The acquisition of MTL Cannabis is expected to be accretive to net revenue, gross margin, and Adjusted EBITDA, with integration planning already underway [5][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve positive Adjusted EBITDA during fiscal 2027, supported by cost-saving initiatives and growth in the Canadian business [10][16] - The company is taking proactive measures to mitigate the financial impact of proposed changes to the Veterans Reimbursement Program while maintaining service quality [6][32] - Management highlighted the importance of operational execution, disciplined capital allocation, and achieving positive Adjusted EBITDA as key priorities for sustainable long-term success [16][19] Other Important Information - A $150 million recapitalization was completed post-quarter end, improving liquidity and extending debt maturities to 2031 [5][11] - The company is focused on maintaining sufficient cash for flexibility and potential strategic opportunities while planning for MTL integration costs of approximately CAD 40 million to CAD 50 million [40] Q&A Session Summary Question: Expectations for international business growth opportunities - Management indicated that they are confident in their ability to meet demand in Europe and are working on improving supply capabilities [21][22][24] Question: Gross margin expectations for legacy business and MTL - Management expects a blended gross margin in the mid- to high 30s, with the MTL acquisition anticipated to enhance gross margins [25][27] Question: Clarification on positive Adjusted EBITDA expectations - Management aims for positive Adjusted EBITDA during fiscal 2027, with efforts to achieve this as soon as possible [29] Question: Indebtedness maturities and equity issuance - Management expects reduced utilization of the ATM in the coming quarters due to improved balance sheet position [30] Question: Domestic medical business and veterans reimbursement proposal - Management is actively working to address the proposed reduction in reimbursement rates for veterans, emphasizing the importance of maintaining care quality [32][34] Question: Cash management and MTL integration costs - Management plans to maintain sufficient cash for flexibility and estimates integration costs for MTL to be between CAD 40 million and CAD 50 million [40]

Ventas (NYSE:VTR) Q4 2025 Earnings call February 06, 2026 10:00 AM ET Company ParticipantsBJ Grant - SVP of Investor RelationsDebra A. Cafaro - Chairman and CEOFarrell Granath - Equity Research AssociateJ. Justin Hutchens - EVP of Senior Housing and Chief Investment OfficerJim Kammert - Managing DirectorJohn Kilichowski - Executive Director Equity ResearchJuan C. Sanabria - Managing DirectorJulien Blouin - VP of Real Estate Global Investment ResearchMichael Carroll - Managing DirectorNick Joseph - Global He ...